The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Zai Lab Limited ADR (NASDAQ: ZLAB) closed the day trading at $19.76 up 2.12% from the previous closing price of $19.35. In other words, the price has increased by $2.12 from its previous closing price. On the day, 0.79 million shares were traded. ZLAB stock price reached its highest trading level at $19.99 during the session, while it also had its lowest trading level at $18.91.
Ratios:
For a better understanding of ZLAB, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.29 and its Current Ratio is at 3.46. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on December 14, 2023, initiated with a Overweight rating and assigned the stock a target price of $47.50.
On August 10, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $70.
On January 21, 2022, Macquarie started tracking the stock assigning a Outperform rating and target price of $64.Macquarie initiated its Outperform rating on January 21, 2022, with a $64 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 03 ’24 when GAYNOR RICHARD bought 2,500 shares for $19.50 per share.
Edmondson Frazor Titus III sold 1,924 shares of ZLAB for $32,619 on Aug 19 ’24. The Chief Legal Officer now owns 28,872 shares after completing the transaction at $16.95 per share. On Aug 16 ’24, another insider, Smiley Joshua L, who serves as the insider of the company, sold 4,352 shares for $16.67 each. As a result, the insider received 72,561 and left with 43,232 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZLAB now has a Market Capitalization of 1968269952 and an Enterprise Value of 18632880128. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.07 while its Price-to-Book (P/B) ratio in mrq is 2.75. Its current Enterprise Value per Revenue stands at 57.739 whereas that against EBITDA is -54.229.
Stock Price History:
Over the past 52 weeks, ZLAB has reached a high of $31.22, while it has fallen to a 52-week low of $13.48. The 50-Day Moving Average of the stock is 9.92%, while the 200-Day Moving Average is calculated to be -2.64%.
Shares Statistics:
Over the past 3-months, ZLAB traded about 553.98K shares per day on average, while over the past 10 days, ZLAB traded about 680490 shares per day. A total of 99.12M shares are outstanding, with a floating share count of 98.53M. Insiders hold about 0.59% of the company’s shares, while institutions hold 42.97% stake in the company. Shares short for ZLAB as of 1723680000 were 4714558 with a Short Ratio of 8.51, compared to 1721001600 on 2959071. Therefore, it implies a Short% of Shares Outstanding of 4714558 and a Short% of Float of 5.239999699999999.
Earnings Estimates
Its stock is currently analyzed by 6.0 different market analysts. The consensus estimate for the next quarter is -$0.78, with high estimates of -$0.57 and low estimates of -$0.94.
Analysts are recommending an EPS of between -$2.55 and -$3.16 for the fiscal current year, implying an average EPS of -$2.94. EPS for the following year is -$1.75, with 8.0 analysts recommending between -$1.02 and -$2.41.
Revenue Estimates
6 analysts predict $104.56M in revenue for the current quarter. It ranges from a high estimate of $110.06M to a low estimate of $97.1M. As of the current estimate, Zai Lab Limited ADR’s year-ago sales were $69.23MFor the next quarter, 6 analysts are estimating revenue of $110.52M. There is a high estimate of $119.86M for the next quarter, whereas the lowest estimate is $101.8M.
A total of 9 analysts have provided revenue estimates for ZLAB’s current fiscal year. The highest revenue estimate was $417.58M, while the lowest revenue estimate was $386.5M, resulting in an average revenue estimate of $399.8M. In the same quarter a year ago, actual revenue was $266.72MBased on 9 analysts’ estimates, the company’s revenue will be $602.07M in the next fiscal year. The high estimate is $690M and the low estimate is $536.2M.
